NDLI: Microbial heparin/heparan sulphate lyases: potential and applications

Content Provider	Springer Nature Link
Author	Tripathi, C. K. M. Banga, Jaspreet Mishra, Vikas
Copyright Year	2012
Abstract	Heparin/heparan sulphate glycosaminoglycans (HSGAGs) are composed of linear chains of 20–100 disaccharide units of N-acetylated d-glucosamine α (1–4) linked to glucuronic acid. HSGAGs are widely distributed on the cell surface and extracellular cell matrix of virtually every mammalian cell type and play critical role in regulating numerous functions of blood vessel wall, blood coagulation, inflammation response and cell differentiation. These glycosaminoglycans present in this extracellular environment very significantly influence the blood coagulation system and cardiovascular functions. Recent studies have investigated the mechanism by which cancer causes thrombosis and emphasizes the importance of the coagulation system in angiogenesis and tumour metastasis. Heparan sulphate/heparin lyases or heparinases are a class of enzymes that are capable of specifically cleaving the (1–4) glycosidic linkages in heparin and heparan sulphate to generate biologically active oligosaccharides with substantially significant and distinct clinical, pharmaceutical and prophylactic/therapeutic applications. Bioavailability and pharmacokinetic behaviour and characteristics of these oligosaccharides vary significantly depending on the origin/nature of the substrate (heparin or heparan sulphate-like glycosaminoglycans), the source of enzyme and method of preparation. Various microorganisms are reported/patented to produce these enzymes with different properties. Heparinases are commercially used for the depolymerization of unfractionated heparin to produce low molecular weight heparins (LMWHs), an effective anticoagulant. Individual LMWHs are chemically different and unique and thus cannot be interchanged therapeutically. Heparinases and LMWHs are reported to control angiogenesis and metastasis also. This review catalogues the degradation of HSGAGs by microbial heparin/heparan sulphate lyases and their potential either specific to the enzymes or with the dual role for generation of oligosaccharides for a new generation of compounds, as shown by various laboratory or clinical studies.
Starting Page	307
Ending Page	321
Page Count	15
File Format	PDF
ISSN	01757598
Journal	Applied Microbiology and Biotechnology
Volume Number	94
Issue Number	2
e-ISSN	14320614
Language	English
Publisher	Springer-Verlag
Publisher Date	2012-03-06
Publisher Place	Berlin, Heidelberg
Access Restriction	Subscribed
Subject Keyword	Glycosaminoglycans Heparin lyases Low molecular weight heparins (LMWHs) Neovascularization Unfractionated heparin (UFH) Microbiology Biotechnology Microbial Genetics and Genomics
Content Type	Text
Resource Type	Article
Subject	Medicine Applied Microbiology and Biotechnology Biotechnology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

DIFFERENTIAL NEUTRALIZATION OF UNFRACTIONATED HEPARIN (UH) AND LOW MOLECULAR WEIGHT HEPARINS (LMWHS) BY HUMAN PLATELET FACTOR FOUR (PF-4)

Anticoagulant heparan sulfate: structural specificity and biosynthesis

Appropriate Use of Low-Molecular-Weight Heparins (LMWHs)

Osteoblast Growth Inhibition by Unfractionated Heparin and by Low Molecular Weight Heparins:

Microbial heparin/heparan sulphate lyases: potential and applications

Similar Documents

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

DIFFERENTIAL NEUTRALIZATION OF UNFRACTIONATED HEPARIN (UH) AND LOW MOLECULAR WEIGHT HEPARINS (LMWHS) BY HUMAN PLATELET FACTOR FOUR (PF-4)

Anticoagulant heparan sulfate: structural specificity and biosynthesis

Appropriate Use of Low-Molecular-Weight Heparins (LMWHs)

Osteoblast Growth Inhibition by Unfractionated Heparin and by Low Molecular Weight Heparins:

Microbial heparin/heparan sulphate lyases: potential and applications